Literature DB >> 14747370

The classification of glomerulonephritis in systemic lupus erythematosus revisited.

Jan J Weening1, Vivette D D'Agati, Melvin M Schwartz, Surya V Seshan, Charles E Alpers, Gerald B Appel, James E Balow, Jan A Bruijn, Terence Cook, Franco Ferrario, Agnes B Fogo, Ellen M Ginzler, Lee Hebert, Gary Hill, Prue Hill, J Charles Jennette, Norella C Kong, Philippe Lesavre, Michael Lockshin, Lai-Meng Looi, Hirofumi Makino, Luiz A Moura, Michio Nagata.   

Abstract

The currently used classification reflects our understanding of the pathogenesis of the various forms of lupus nephritis, but clinicopathologic studies have revealed the need for improved categorization and terminology. Based on the 1982 classification published under the auspices of the World Health Organization (WHO) and subsequent clinicopathologic data, we propose that class I and II be used for purely mesangial involvement (I, mesangial immune deposits without mesangial hypercellularity; II, mesangial immune deposits with mesangial hypercellularity); class III for focal glomerulonephritis (involving <50% of total number of glomeruli) with subdivisions for active and sclerotic lesions; class IV for diffuse glomerulonephritis (involving > or = 50% of total number of glomeruli) either with segmental (class IV-S) or global (class IV-G) involvement, and also with subdivisions for active and sclerotic lesions; class V for membranous lupus nephritis; and class VI for advanced sclerosing lesions]. Combinations of membranous and proliferative glomerulonephritis (i.e., class III and V or class IV and V) should be reported individually in the diagnostic line. The diagnosis should also include entries for any concomitant vascular or tubulointerstitial lesions. One of the main advantages of the current revised classification is that it provides a clear and unequivocal description of the various lesions and classes of lupus nephritis, allowing a better standardization and lending a basis for further clinicopathologic studies. We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification.

Entities:  

Mesh:

Year:  2004        PMID: 14747370     DOI: 10.1097/01.asn.0000108969.21691.5d

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  528 in total

1.  Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus.

Authors:  Rina Mina; Emily von Scheven; Stacy P Ardoin; B Anne Eberhard; Marilynn Punaro; Norman Ilowite; Joyce Hsu; Marisa Klein-Gitelman; L Nandini Moorthy; Eyal Muscal; Suhas M Radhakrishna; Linda Wagner-Weiner; Matthew Adams; Peter Blier; Lenore Buckley; Elizabeth Chalom; Gaëlle Chédeville; Andrew Eichenfield; Natalya Fish; Michael Henrickson; Aimee O Hersh; Roger Hollister; Olcay Jones; Lawrence Jung; Deborah Levy; Jorge Lopez-Benitez; Deborah McCurdy; Paivi M Miettunen; Ana I Quintero-del Rio; Deborah Rothman; Ornella Rullo; Natasha Ruth; Laura E Schanberg; Earl Silverman; Nora G Singer; Jennifer Soep; Reema Syed; Larry B Vogler; Ali Yalcindag; Cagri Yildirim-Toruner; Carol A Wallace; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-03       Impact factor: 4.794

2.  Soluble VEGF receptor 1 promotes endothelial injury in children and adolescents with lupus nephritis.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Heiko Billing; Burkhard Tönshoff; Dieter Haffner; Jörg Dötsch; Gottfried Wechselberger; Lutz T Weber; Elisabeth Steichen-Gersdorf
Journal:  Pediatr Nephrol       Date:  2011-12-07       Impact factor: 3.714

3.  Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes.

Authors:  Catharina M Haring; Anke Rietveld; Jan A J G van den Brand; Jo H M Berden
Journal:  J Am Soc Nephrol       Date:  2011-10-27       Impact factor: 10.121

4.  Markers of childhood lupus nephritis indicating disease activity.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Dieter Haffner; Heiko Billing; Burkhard Tönshoff; Sophia Ross; Jörg Dötsch; Oliver Amon; Henry Fehrenbach; Christian Steuber; Antje Beissert; Josef Hager; Gottfried Wechselberger; Lutz T Weber; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2010-12-22       Impact factor: 3.714

5.  Mayo Clinic/Renal Pathology Society Consensus Report on Pathologic Classification, Diagnosis, and Reporting of GN.

Authors:  Sanjeev Sethi; Mark Haas; Glen S Markowitz; Vivette D D'Agati; Helmut G Rennke; J Charles Jennette; Ingeborg M Bajema; Charles E Alpers; Anthony Chang; Lynn D Cornell; Fernando G Cosio; Agnes B Fogo; Richard J Glassock; Sundaram Hariharan; Neeraja Kambham; Donna J Lager; Nelson Leung; Michael Mengel; Karl A Nath; Ian S Roberts; Brad H Rovin; Surya V Seshan; Richard J H Smith; Patrick D Walker; Christopher G Winearls; Gerald B Appel; Mariam P Alexander; Daniel C Cattran; Carmen Avila Casado; H Terence Cook; An S De Vriese; Jai Radhakrishnan; Lorraine C Racusen; Pierre Ronco; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-11-13       Impact factor: 10.121

6.  MiR-663a/MiR-423-5p are involved in the pathogenesis of lupus nephritis via modulating the activation of NF-κB by targeting TNIP2.

Authors:  Weisong Wang; Junjie Gao; Fangli Wang
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

7.  Juvenile systemic lupus erythematosus: a single-center experience from southern Turkey.

Authors:  Sibel Balci; Rabia Miray Kisla Ekinci; Aysun Karabay Bayazit; Engin Melek; Dilek Dogruel; Derya Ufuk Altintas; Mustafa Yilmaz
Journal:  Clin Rheumatol       Date:  2019-01-16       Impact factor: 2.980

Review 8.  Reviewing the recommendations for lupus in children.

Authors:  Zehra Serap Arıcı; Ezgi Deniz Batu; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

9.  IFN regulatory factor 5 is required for disease development in the FcgammaRIIB-/-Yaa and FcgammaRIIB-/- mouse models of systemic lupus erythematosus.

Authors:  Christophe Richez; Kei Yasuda; Ramon G Bonegio; Amanda A Watkins; Tamar Aprahamian; Patricia Busto; Rocco J Richards; Chih Long Liu; Regina Cheung; Paul J Utz; Ann Marshak-Rothstein; Ian R Rifkin
Journal:  J Immunol       Date:  2009-12-09       Impact factor: 5.422

10.  Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy.

Authors:  Howard A Austin; Gabor G Illei; Michelle J Braun; James E Balow
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.